Informations d’entreprise

Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time —

ESPOO, Finland, April 08, 2021 — Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, for an enterprise value of approximately €668 million ($795 million).  This includes a cash payment of approximately €600 million ($714 million) for Mobidiag’s equity, and net debt of approximately €68 million ($81 million).

• Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
• One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

FINLAND, Espoo, March 1^st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag^® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.

These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The See poster

Mobidiag Ltd. today announces that it has signed an agreement with XboXLab for the distribution of its molecular diagnostic products Amplidiag^® and Novodiag^® in Norway.

We are very pleased to expand our distribution network and be able to provide Norwegian clinical laboratories with our innovative molecular diagnostic solutions.

For more information, please contact :
Henning Jansen
+47 40 33 00 11
henning.jansen@xboxlab.no
www.xboxlab.se

Mobidiag products are also available throughout Europe and the Middle East. Visit our See poster

Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019

New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases

CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release

Antibody test for detection of past COVID-19 infections

Secure supply chain and in-house manufacturing capabilities to meet demand

Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;

provides safety for users with a closed system;

easy to use with no need for highly trained personnel enabling decentralized testing.

– Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance

– Currently set up for routine use in main Finnish clinical labs with capacity to test up to 4,000 samples per day

Mobidiag Ltd. announces that it has received emergency use authorization in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France. Mobidiag w

Novodiag^® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas

Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.

The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.

The new Novodiag® test will operate using a rapid ‘sample-in, result-out’ system, allowing the rapid detection of both novel coronavirus and influenzas in around 30 minutes. In addition, the fully automa

ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).

Mobidiag is harnessing the power of its Novodiag platform to develop a fast, simple and reliable syndromic assay to detect sepsis within two hours, directly from a patient’s bl